PTGS1 and asthma: N-ERD is clinically characterised by the presence of asthma, chronic rhinosinusitis with nasal polyposis, and exacerbation of respiratory symptoms on exposure to substances having cyclo-oxygenase 1 (COX-1) inhibiting activity [1, 3•].